7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-4-methyl-3-phenyl-2H-chromen-2-one | 866887-44-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-4-methyl-3-phenyl-2H-chromen-2-one
• 英文别名: 7-[[(3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-3a,4,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4-yl]oxy]-4-methyl-3-phenylchromen-2-one
• CAS: 866887-44-7
• 化学式: C₂₅H₂₄O₈
• 分子量: 452.461
• InChiKey: SOWIMKYXOSLABR-ZZLPTCMGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  89.5
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-4-methyl-3-phenyl-2H-chromen-2-one 在 氨 作用下， 生成 7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-4-methyl-3-phenyl-2H-chromen-2-one 、 (3R,4S,5R,6R)-4-hydroxy-3-methoxy-2,2-dimethyl-6-(4-methyl-2-oxo-3-phenyl-2H-chromen-7-yloxy)tetrahydro-2H-pyran-5-yl carbamate 、 (2R,3R,4R,5R)-3-hydroxy-5-methoxy-6,6-dimethyl-2-(4-methyl-2-oxo-3-phenyl-2H-chromen-7-yloxy)tetrahydro-2H-pyran-4-yl carbamate
  参考文献：
  名称：

  Novobiocin：重新设计用于选择性抑制 Hsp90 的 DNA 旋转酶抑制剂

  摘要：

  Novobiocin 是香豆霉素抗生素家族的成员，是一种成熟的 DNA 促旋酶抑制剂。最近的研究表明，新生霉素在 Hsp90 的 C 末端与以前未被识别的 ATP 结合位点结合，并在大约 700 microM 处诱导 Hsp90 依赖性客户蛋白的降解。为了开发更有效的 C 末端结合位点抑制剂，制备了新生霉素类似物库并揭示了初始结构-活性关系。这些数据表明香豆素环的 4-羟基部分和新糖附属物的 3'-氨基甲酸酯对 Hsp90 抑制活性有害。为了证实这些发现，制备了 4-去羟基新生霉素 (DHN1) 和 3'-去氨基甲酰基-4-去羟基新生霉素 (DHN2)，并针对 Hsp90 进行了评估。这两种化合物都比天然产物更有效，而且 DHN2 被证明比 DHN1 更活跃。为了确定这些部分是否对 DNA 促旋酶抑制很重要，测试了这些化合物抑制 DNA 促旋酶的能力，并发现它们显示出促旋酶活性的显着降低。因此，我们已经建立了第一组明确区分

  DOI：

  10.1021/ja065793p
• 作为产物：
  描述：

  noviose carbonate trichloroacetimidate 、 7-hydroxy-4-methyl-3-phenyl-chromen-2-one 在 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以73%的产率得到7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-4-methyl-3-phenyl-2H-chromen-2-one
  参考文献：
  名称：

  Hsp90 Inhibitors Identified from a Library of Novobiocin Analogues

  摘要：

  Novobiocin is a C-terminal inhibitor of the Hsp90 protein folding machinery, which is responsible for the conformational maturation of numerous proteins involved in cancer growth and survival. Due to novobiocin's poor inhibitory activity ( approximately 700 muM), very little attention has been paid toward the development of novobiocin analogues for Hsp90 inhibition. In this study, a parallel library of 20 novobiocin derivatives was prepared and the biological activity of each evaluated by Western blot analysis of Hsp90 client proteins. A4 was found to be a potent inhibitor of Hsp90 as determined by its ability to cause the degradation of several Hsp90 client proteins in both breast and prostate cancer cell lines. In the presence of 1 muM A4, several Hsp90 client proteins were degraded, including AKT, Her2, Hif-1alpha, and the androgen receptor.

  DOI：

  10.1021/ja0535864

文献信息

• NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE
  申请人：Calvet James P.

  公开号：US20110082098A1

  公开（公告）日：2011-04-07

  Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.

  新比奴霉素类似物在治疗、抑制和/或预防自体显性多囊肾病（ADPKD）中的囊肿形成方法中是有用的。本公开提供了治疗ADPKD的方法，包括给予香豆素-3-羧酰胺新比奴霉素类似物的治疗有效量。因此，该方法可以包括给予新比奴霉素类似物的治疗有效量，以降低mTOR途径磷酸化蛋白P-mTOR、P-Akt和P-S6K的水平，或其组合。此外，该方法可以包括给予新比奴霉素类似物的治疗有效量，以降低Hsp-90客体蛋白CFTR、ErbB2、c-Raf和Cdk4的水平，或其组合。
• Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
  申请人：Blagg Brian

  公开号：US20070270452A1

  公开（公告）日：2007-11-22

  Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.

  诺伐霉素类似物及含有这种化合物的制药组合物，可用于治疗和/或预防神经退行性疾病和自身免疫性疾病。
• Heat shock protein 90 inhibitor dosing methods
  申请人：Rajewski Roger A.

  公开号：US20100022635A1

  公开（公告）日：2010-01-28

  The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof such that no more than a single dose is administered within a period of about 7 days.

  该披露提供了新型的Hsp90抑制剂用于治疗或预防神经退行性疾病、自身免疫疾病或癌症的剂量方案。该方法涉及向需要治疗的受试者施用至少一种Hsp90抑制剂的治疗有效剂量的一个或多个剂量，以使在大约7天的时间内不会施用超过单一剂量。
• NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS
  申请人：Blagg Brian S.J.

  公开号：US20100105630A1

  公开（公告）日：2010-04-29

  Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.

  诺伐霉素类似物和含有这些化合物的药物组合物，可用于治疗和/或预防神经退行性疾病和自身免疫性疾病。
• NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES
  申请人：Blagg Brian S. J.

  公开号：US20120252745A1

  公开（公告）日：2012-10-04

  The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.

  本公开提供了具有替代noviose的诺维菌素类似物，其在癌症治疗中作为Hsp90抑制剂是有用的。